Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy
In a randomized crossover study 57 cancer patients receiving chemotherapy with high emetic potential were treated with low-dose levonantradol or standard-dose metoclopramide and crossed over to the other antiemetic drug in the next identical chemotherapy cycle. In the 45 patients evaluable for treat...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 1984-01, Vol.13 (2), p.123-125 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 125 |
|---|---|
| container_issue | 2 |
| container_start_page | 123 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 13 |
| creator | HEIM, M. E QUEISSER, W ALTENBURG, H.-P |
| description | In a randomized crossover study 57 cancer patients receiving chemotherapy with high emetic potential were treated with low-dose levonantradol or standard-dose metoclopramide and crossed over to the other antiemetic drug in the next identical chemotherapy cycle. In the 45 patients evaluable for treatment response the antiemetic efficacy of levonantradol was significantly better: 62% had less nausea and 58% less vomiting, as against 11% and 16%, respectively, with metoclopramide. Patient preference for antiemetic treatment was levonantradol in 49% and metoclopramide in 22% of cases. Levonantradol treatment was accompanied by a relatively high incidence of side-effects (71%) compared with metoclopramide (29%). The antiemetic efficacy of each single drug was incomplete in most cases of this trial, and antiemetic combination therapy is recommended for further trials. |
| doi_str_mv | 10.1007/BF00257128 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00257128</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>6467496</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-45eb93912b4fed3b6f72daf4318e2d9bc9aaf401bd31ec71917784d00c671ce23</originalsourceid><addsrcrecordid>eNpFkM9LwzAYhoMoc04v3oUcPAnV_GqzHnU4FQaC6LmkyVcXaZuSZIN59R83bmOePj7ehwfeF6FLSm4pIfLuYU4IyyVl0yM0poKzjEwFP0ZjwoXIcknEKToL4YsQIijnIzQqRCFFWYzRz5vqjevsNxisvQvBrcHjEFdmg12D4xKw6qOFDqLVWOlo1zZuoxbWrk-ZV8a1CTI4MU63bvCqswaw7bFWvU66QSVDHwP2oCEJ-k-sl9C5ZPdq2Jyjk0a1AS72d4I-5o_vs-ds8fr0MrtfZJpTGjORQ13ykrJaNGB4XTSSGdUITqfATFnrUqWP0NpwClrSkko5FYYQXUiqgfEJutl5t0U9NNXgbaf8pqKk-huy-h8ywVc7eFjVHZgDul8u5df7XAWt2sanqjYcsJLwguWc_wL-234H</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy</title><source>MEDLINE</source><source>SpringerLink Journals (MCLS)</source><creator>HEIM, M. E ; QUEISSER, W ; ALTENBURG, H.-P</creator><creatorcontrib>HEIM, M. E ; QUEISSER, W ; ALTENBURG, H.-P</creatorcontrib><description>In a randomized crossover study 57 cancer patients receiving chemotherapy with high emetic potential were treated with low-dose levonantradol or standard-dose metoclopramide and crossed over to the other antiemetic drug in the next identical chemotherapy cycle. In the 45 patients evaluable for treatment response the antiemetic efficacy of levonantradol was significantly better: 62% had less nausea and 58% less vomiting, as against 11% and 16%, respectively, with metoclopramide. Patient preference for antiemetic treatment was levonantradol in 49% and metoclopramide in 22% of cases. Levonantradol treatment was accompanied by a relatively high incidence of side-effects (71%) compared with metoclopramide (29%). The antiemetic efficacy of each single drug was incomplete in most cases of this trial, and antiemetic combination therapy is recommended for further trials.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/BF00257128</identifier><identifier>PMID: 6467496</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adolescent ; Adult ; Aged ; Antiemetics - adverse effects ; Antiemetics - therapeutic use ; Antineoplastic Agents - adverse effects ; Biological and medical sciences ; Drug Therapy, Combination ; Drug toxicity and drugs side effects treatment ; Female ; Humans ; Male ; Medical sciences ; Metoclopramide - therapeutic use ; Middle Aged ; Nausea - drug therapy ; Neoplasms - drug therapy ; Pharmacology. Drug treatments ; Phenanthridines - therapeutic use ; Random Allocation ; Toxicity: digestive system ; Vomiting - drug therapy</subject><ispartof>Cancer chemotherapy and pharmacology, 1984-01, Vol.13 (2), p.123-125</ispartof><rights>1985 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-45eb93912b4fed3b6f72daf4318e2d9bc9aaf401bd31ec71917784d00c671ce23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9036253$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6467496$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HEIM, M. E</creatorcontrib><creatorcontrib>QUEISSER, W</creatorcontrib><creatorcontrib>ALTENBURG, H.-P</creatorcontrib><title>Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>In a randomized crossover study 57 cancer patients receiving chemotherapy with high emetic potential were treated with low-dose levonantradol or standard-dose metoclopramide and crossed over to the other antiemetic drug in the next identical chemotherapy cycle. In the 45 patients evaluable for treatment response the antiemetic efficacy of levonantradol was significantly better: 62% had less nausea and 58% less vomiting, as against 11% and 16%, respectively, with metoclopramide. Patient preference for antiemetic treatment was levonantradol in 49% and metoclopramide in 22% of cases. Levonantradol treatment was accompanied by a relatively high incidence of side-effects (71%) compared with metoclopramide (29%). The antiemetic efficacy of each single drug was incomplete in most cases of this trial, and antiemetic combination therapy is recommended for further trials.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antiemetics - adverse effects</subject><subject>Antiemetics - therapeutic use</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Drug Therapy, Combination</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metoclopramide - therapeutic use</subject><subject>Middle Aged</subject><subject>Nausea - drug therapy</subject><subject>Neoplasms - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenanthridines - therapeutic use</subject><subject>Random Allocation</subject><subject>Toxicity: digestive system</subject><subject>Vomiting - drug therapy</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM9LwzAYhoMoc04v3oUcPAnV_GqzHnU4FQaC6LmkyVcXaZuSZIN59R83bmOePj7ehwfeF6FLSm4pIfLuYU4IyyVl0yM0poKzjEwFP0ZjwoXIcknEKToL4YsQIijnIzQqRCFFWYzRz5vqjevsNxisvQvBrcHjEFdmg12D4xKw6qOFDqLVWOlo1zZuoxbWrk-ZV8a1CTI4MU63bvCqswaw7bFWvU66QSVDHwP2oCEJ-k-sl9C5ZPdq2Jyjk0a1AS72d4I-5o_vs-ds8fr0MrtfZJpTGjORQ13ykrJaNGB4XTSSGdUITqfATFnrUqWP0NpwClrSkko5FYYQXUiqgfEJutl5t0U9NNXgbaf8pqKk-huy-h8ywVc7eFjVHZgDul8u5df7XAWt2sanqjYcsJLwguWc_wL-234H</recordid><startdate>19840101</startdate><enddate>19840101</enddate><creator>HEIM, M. E</creator><creator>QUEISSER, W</creator><creator>ALTENBURG, H.-P</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19840101</creationdate><title>Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy</title><author>HEIM, M. E ; QUEISSER, W ; ALTENBURG, H.-P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-45eb93912b4fed3b6f72daf4318e2d9bc9aaf401bd31ec71917784d00c671ce23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antiemetics - adverse effects</topic><topic>Antiemetics - therapeutic use</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Drug Therapy, Combination</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metoclopramide - therapeutic use</topic><topic>Middle Aged</topic><topic>Nausea - drug therapy</topic><topic>Neoplasms - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenanthridines - therapeutic use</topic><topic>Random Allocation</topic><topic>Toxicity: digestive system</topic><topic>Vomiting - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HEIM, M. E</creatorcontrib><creatorcontrib>QUEISSER, W</creatorcontrib><creatorcontrib>ALTENBURG, H.-P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HEIM, M. E</au><au>QUEISSER, W</au><au>ALTENBURG, H.-P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>1984-01-01</date><risdate>1984</risdate><volume>13</volume><issue>2</issue><spage>123</spage><epage>125</epage><pages>123-125</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>In a randomized crossover study 57 cancer patients receiving chemotherapy with high emetic potential were treated with low-dose levonantradol or standard-dose metoclopramide and crossed over to the other antiemetic drug in the next identical chemotherapy cycle. In the 45 patients evaluable for treatment response the antiemetic efficacy of levonantradol was significantly better: 62% had less nausea and 58% less vomiting, as against 11% and 16%, respectively, with metoclopramide. Patient preference for antiemetic treatment was levonantradol in 49% and metoclopramide in 22% of cases. Levonantradol treatment was accompanied by a relatively high incidence of side-effects (71%) compared with metoclopramide (29%). The antiemetic efficacy of each single drug was incomplete in most cases of this trial, and antiemetic combination therapy is recommended for further trials.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>6467496</pmid><doi>10.1007/BF00257128</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 1984-01, Vol.13 (2), p.123-125 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF00257128 |
| source | MEDLINE; SpringerLink Journals (MCLS) |
| subjects | Adolescent Adult Aged Antiemetics - adverse effects Antiemetics - therapeutic use Antineoplastic Agents - adverse effects Biological and medical sciences Drug Therapy, Combination Drug toxicity and drugs side effects treatment Female Humans Male Medical sciences Metoclopramide - therapeutic use Middle Aged Nausea - drug therapy Neoplasms - drug therapy Pharmacology. Drug treatments Phenanthridines - therapeutic use Random Allocation Toxicity: digestive system Vomiting - drug therapy |
| title | Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T18%3A08%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomized%20crossover%20study%20of%20the%20antiemetic%20activity%20of%20levonantradol%20and%20metoclopramide%20in%20cancer%20patients%20receiving%20chemotherapy&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=HEIM,%20M.%20E&rft.date=1984-01-01&rft.volume=13&rft.issue=2&rft.spage=123&rft.epage=125&rft.pages=123-125&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/BF00257128&rft_dat=%3Cpubmed_cross%3E6467496%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/6467496&rfr_iscdi=true |